184 related articles for article (PubMed ID: 31990564)
1. Interactions of Oral Molecular Excipients with Breast Cancer Resistance Protein, BCRP.
Zou L; Pottel J; Khuri N; Ngo HX; Ni Z; Tsakalozou E; Warren MS; Huang Y; Shoichet BK; Giacomini KM
Mol Pharm; 2020 Mar; 17(3):748-756. PubMed ID: 31990564
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Intestinal Transport and Absorption of Topotecan, a BCRP Substrate, by Various Pharmaceutical Excipients and Their Inhibitory Mechanisms of BCRP Transporter.
Sawangrat K; Yamashita S; Tanaka A; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2019 Mar; 108(3):1315-1325. PubMed ID: 30389568
[TBL] [Abstract][Full Text] [Related]
3. Effects of Various Pharmaceutical Excipients on the Intestinal Transport and Absorption of Sulfasalazine, a Typical Substrate of Breast Cancer Resistance Protein Transporter.
Sawangrat K; Morishita M; Kusamori K; Katsumi H; Sakane T; Yamamoto A
J Pharm Sci; 2018 Nov; 107(11):2946-2956. PubMed ID: 30053556
[TBL] [Abstract][Full Text] [Related]
4. Improvement of the oral drug absorption of topotecan through the inhibition of intestinal xenobiotic efflux transporter, breast cancer resistance protein, by excipients.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
Drug Metab Dispos; 2007 Jul; 35(7):1142-8. PubMed ID: 17446265
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the inhibition of breast cancer resistance protein-mediated efflux of mitoxantrone by pharmaceutical excipients.
Yamagata T; Morishita M; Kusuhara H; Takayama K; Benameur H; Sugiyama Y
Int J Pharm; 2009 Mar; 370(1-2):216-9. PubMed ID: 19118611
[TBL] [Abstract][Full Text] [Related]
6. Interactions of the major effective components in Shengmai formula with breast cancer resistance protein at the cellular and vesicular levels.
Wu L; Liu J; Hou J; Zhan T; Yuan L; Liu F; Xiong Y; Hu J; Xia C
Biomed Pharmacother; 2021 Jan; 133():110939. PubMed ID: 33232930
[TBL] [Abstract][Full Text] [Related]
7. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
8. Effect of excipients on breast cancer resistance protein substrate uptake activity.
Yamagata T; Kusuhara H; Morishita M; Takayama K; Benameur H; Sugiyama Y
J Control Release; 2007 Dec; 124(1-2):1-5. PubMed ID: 17900739
[TBL] [Abstract][Full Text] [Related]
9. Intestinal breast cancer resistance protein (BCRP) requires Janus kinase 3 activity for drug efflux and barrier functions in obesity.
Mishra J; Simonsen R; Kumar N
J Biol Chem; 2019 Nov; 294(48):18337-18348. PubMed ID: 31653704
[TBL] [Abstract][Full Text] [Related]
10. Improved In vivo Effect of Chrysin as an Absorption Enhancer Via the Preparation of Ternary Solid Dispersion with Brij®L4 and Aminoclay.
Lee SH; Lee YS; Song JG; Han HK
Curr Drug Deliv; 2019; 16(1):86-92. PubMed ID: 30246640
[TBL] [Abstract][Full Text] [Related]
11. Characterization and Validation of Canine P-Glycoprotein-Deficient MDCK II Cell Lines for Efflux Substrate Screening.
Ye D; Harder A; Fang Z; Weinheimer M; Laplanche L; Mezler M
Pharm Res; 2020 Sep; 37(10):194. PubMed ID: 32918191
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific effects of excipients on oral drug bioavailability.
Mai Y; Madla CM; Shao H; Qin Y; Merchant HA; Murdan S; Basit AW
Int J Pharm; 2022 Dec; 629():122365. PubMed ID: 36336203
[TBL] [Abstract][Full Text] [Related]
13. Virtual Screening of DrugBank Reveals Two Drugs as New BCRP Inhibitors.
Montanari F; Cseke A; Wlcek K; Ecker GF
SLAS Discov; 2017 Jan; 22(1):86-93. PubMed ID: 27401583
[TBL] [Abstract][Full Text] [Related]
14. Novel inhibitors of breast cancer resistance protein (BCRP, ABCG2) among marketed drugs.
Deng F; Sjöstedt N; Santo M; Neuvonen M; Niemi M; Kidron H
Eur J Pharm Sci; 2023 Feb; 181():106362. PubMed ID: 36529162
[TBL] [Abstract][Full Text] [Related]
15. Bisphenol A Inhibits the Transporter Function of the Blood-Brain Barrier by Directly Interacting with the ABC Transporter Breast Cancer Resistance Protein (BCRP).
Engdahl E; van Schijndel MDM; Voulgaris D; Di Criscio M; Ramsbottom KA; Rigden DJ; Herland A; Rüegg J
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073890
[TBL] [Abstract][Full Text] [Related]
16. Rhinacanthin-C Mediated Herb-Drug Interactions with Drug Transporters and Phase I Drug-Metabolizing Enzymes.
Dunkoksung W; Vardhanabhuti N; Siripong P; Jianmongkol S
Drug Metab Dispos; 2019 Oct; 47(10):1040-1049. PubMed ID: 31399508
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the breast cancer resistance protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
Reustle A; Fisel P; Renner O; Büttner F; Winter S; Rausch S; Kruck S; Nies AT; Hennenlotter J; Scharpf M; Fend F; Stenzl A; Bedke J; Schwab M; Schaeffeler E
Int J Cancer; 2018 Dec; 143(12):3181-3193. PubMed ID: 30070687
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of 5-Hydroxy-3',4',7-trimethoxyflavone and Related Compounds and Elucidation of Their Reversal Effects on BCRP/ABCG2-Mediated Anticancer Drug Resistance.
Tsunekawa R; Katayama K; Hanaya K; Higashibayashi S; Sugimoto Y; Sugai T
Chembiochem; 2019 Jan; 20(2):210-220. PubMed ID: 30187992
[TBL] [Abstract][Full Text] [Related]
19. Effects of the antiretroviral drug 2'-deoxy-2'-β-fluoro-4'-azidocytidine (FNC) on P-gp, MRP2 and BCRP expressions and functions.
Liu Y; Wang Y; Peng Y; Liu B; Ma F; Jiang J; Wang Q; Chang J
Pharmazie; 2018 Sep; 73(9):503-507. PubMed ID: 30223932
[TBL] [Abstract][Full Text] [Related]
20. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Gupta A; Unadkat JD; Mao Q
J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
